Acadia Pharmaceuticals Reports Third Quarter 2026 Financial Results
Acadia Pharmaceuticals reported Q3 2026 revenues of $420.8 million, with DAYBUE sales at $232.2 million and NUPLAZID sales at $188.6 million. The company raised 2026 DAYBUE net sales guidance to $495-510 million. Positive Phase 2 data for remlifanserin in Alzheimer's disease psychosis was announced, with additional data to be presented at a conference.
How this was made
The 30-second read
Why it matters
The guidance reduction signals weaker sales momentum, potentially prompting short‑term price declines, but the company’s pipeline milestones may provide upside later.
Market read
Earnings and guidance updates are primary drivers for biotech stock moves; this release provides fresh, material information for traders.
What to watch
Upcoming Phase 3 data for remifilanserin and European launch progress could offset short‑term revenue concerns.
Background
Acadia Pharmaceuticals focuses on treatments for Parkinson's disease psychosis and Rett syndrome, with a pipeline in Alzheimer’s disease psychosis and Lewy body dementia psychosis.
Ticker impact
Acadia Pharmaceuticals reported Q3 2026 results and cut its 2026 revenue guidance, lowering total revenue to $1.265 billion and NUPLAZID sales to $760 million.
likely downward pressure as the market prices in the lower guidance
Revenue and product sales guidance were cut, which historically triggers a sell‑off for biotech stocks.
Market effects
May weigh on other rare‑disease biotech peers as guidance cuts raise concerns about market demand.
Limited to U.S. biotech sector; no broader regional effect.
Minimal global impact beyond the niche biotech space.
Counterpoint
If the guidance cut reflects a temporary slowdown and the pipeline remains strong, the stock could rebound on upcoming data.
Key entities
- CompanyAcadia Pharmaceuticals
NASDAQ‑listed biotech (ticker ACAD) reporting Q3 results and guidance.
- ProductNUPLAZID
Acadia's Parkinson's disease psychosis drug.
- ProductDAYBUE
Acadia's Rett syndrome therapy.
